Related Experiment Video
Updated: Sep 7, 2025
07:09
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
11.6K
Fibrinolysis and D-dimer in COVID-19: A Twisted Plot!
Rohan Magoon1, Nitin Choudhary1, Jes Jose2
1Department of Anaesthesia, Atal Bihari Vajpayee Institute of Medical Sciences and Dr Ram Manohar Lohia Hospital, New Delhi, India.
Summary
This commentary discusses immunothrombosis in Coronavirus disease-2019 (COVID-19). It explores recent developments in understanding the complex relationship between COVID-19 and blood clot formation, focusing on thromboembolic risks.
Area of Science:
- Medicine
- Pathophysiology
- Hematology
Background:
- Coronavirus disease-2019 (COVID-19) presents complex pathophysiological challenges.
- Thromboembolic complications are a significant concern in COVID-19 patients.
- The interplay between inflammation and coagulation in COVID-19 requires further elucidation.
Purpose of the Study:
- To review recent advancements in understanding immunothrombosis in COVID-19.
- To discuss the mechanisms linking COVID-19 infection to an increased risk of blood clots.
- To provide insights into the ongoing debate surrounding thromboembolic predisposition in COVID-19.
Main Methods:
- This is a commentary based on a review of current literature.
- It synthesizes recent findings on immunothrombosis related to COVID-19.
- No new experimental data was generated.
Main Results:
- COVID-19 is associated with a heightened risk of thromboembolic events.
- Immunothrombosis, a condition involving inflammation-driven clot formation, is a key feature.
- The exact mechanisms and clinical implications are still under active investigation.
Conclusions:
- Understanding immunothrombosis is crucial for managing COVID-19 patients.
- Further research is needed to clarify the precise role of D-dimer and fibrinolysis.
- Effective strategies to mitigate thromboembolic risk in COVID-19 are essential.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
6.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.8K
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
887
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
887
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
42
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
42
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
31
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
31